34 results about "Ligand coupling" patented technology

An adsorbent composition comprising: a plurality of particles of an acid-activated clay with a predetermined particle size. Each particle may have a surface comprising metal oxides or metal hydroxides and each particle may have a surface modified by coupling the metal oxides to ligands comprising amino-silane coupling agents configured to adsorb impurities. Each amino-silane coupling agents may comprise an alkoxysilane group and an amine group. The alkoxysilane group may couple to the metal oxide or metal peroxide of each particle. The adsorbent composition may comprise the amino-silane coupling agent and the acid-activated clay with a wight ratio between 2:2 and 3:1 (the acid-activated clay: the amino-silane coupling agent). The acid-activated clay may comprise a plurality of pore with a predetermined diameter formed between particles.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

Methods for coupling ligands to composite materials are disclosed. A covalent bond is formed between the functionalized composite material and the ligand as the ligand solution flows through or across the composite material. The composite material can be used as a chromatographic separation medium.

The invention relates to the technical field of organic detection, in particular to a nanoparticle modified quantum dot MOF material and a preparation method and application thereof. A zirconium-based double-ligand metal organic framework material is used as a carrier, a co-reaction accelerant Ti3C2 quantum dot is modified to enhance the electrochemical luminescence reaction efficiency, and copper-gold nanoparticles are loaded to amplify signals. The nanoparticle modified quantum dot MOF material provided by the invention can be prepared into an aptamer biosensor for accurately identifying malathion, and has high sensitivity and high selectivity. According to the invention, a nanoparticle modified quantum dot MOF material is coupled and combined with an aptamer, and an aptamer probe with high electrochemical luminescence activity and specific sensitivity to malathion is constructed. When the malathion acts on the aptamer probe, the malathion is combined with the aptamer in a high affinity manner, the aptamer probe is separated from the surface of the electrode, and meanwhile, an electrochemical luminescence signal is changed, so that the malathion residue in the agricultural product is rapidly detected.

The present invention provides a quantitative measurement method using competitive immunochromatography, which has not been previously reported. The quantitative measurement method comprises: (1) creating a calibration curve based on the signal intensity of a test line according to the concentration of a standard material by using multiple strips, and calculating the concentration of a target analyte by using the calibration curve; (2) when the concentration of the target analyte increases to a significant level on the calibration curve of the standard material, a labeled signal of a detection ligand on a control line remains unchanged in a case where a detection ligand of a target analyte-detection ligand conjugate binds to and saturates a capture ligand on the control line, making it impossible to estimate the concentration beyond that level; however, by designing a binding site for the capture ligand on the control line to be the target analyte of the target analyte-detection ligand conjugate, a high concentration of the target analyte breaks down the triple conjugate of detection ligand-target analyte-capture ligand, leading to dissociation of the labeled detection ligand and thereby weakening the signal (hook effect); and (3) comparing the signal intensity patterns of the test line and the control line according to the calibration curve of the standard material with the signal intensity pattern of a sample target analyte, and determining how far the target analyte is from the saturation point of the detection ligand. This method is characterized in that, in cases where the target analyte is present in an excessively large amount and exceeds the maximum value of a measurement range (dynamic range) of the calibration curve, the calibration curve using multiple strips and the configurations (test line and control line) of an immunochromatographic device are designed differently to distinguish such cases.

The present invention relates to a heterotandem acyclic peptide complex comprising a first peptide ligand that binds to a component present on an immune cell, which is conjugated via a linker to a second peptide ligand that binds to a component present on a cancer cell. The present invention also relates to the use of said heterotandem acyclic peptide complex in preventing, inhibiting, or treating cancer.

The invention relates to an optical waveguide sensor for detecting heavy metal ions in an aqueous solution and a manufacturing method thereof. An optical waveguide sensor includes a substrate surface having a uniform thin layer of ligands coupled thereto with a tin catalyst to form a functionalized substrate surface, where the optical waveguide sensor is configured to interact with an optical wave at an input of the optical waveguide sensor and an aqueous solution in contact with the functionalized substrate surface, the method further includes determining the concentration of the heavy metal ions in the aqueous solution, whereby the heavy metal ions in the aqueous solution form a coordination complex upon contact with a plurality of binding sites available on the functionalized substrate surface, thereby altering the material optical refractive index of the functionalized substrate surface, the alteration corresponding to the concentration of the heavy metal ions. Treating the surface of the substrate to enable the treated surface to couple to the ligand; coupling the treated substrate surface with the ligand to form a uniform thin layer of ligand on the substrate surface, thereby forming a functionalized substrate surface; and cleaning the functionalized substrate surface with dilute nitric acid wherein the coupling of the treated substrate surface with a ligand is carried out with a tin catalyst, the selection of the ligand varying depending on the type of substrate surface and the type of heavy metal ion to be detected.

This disclosure concerns linkage groups and uses thereof for conjugating ligands to nucleic acids. Also provided are oligonucleotide-ligand conjugates containing the linkage group, and uses thereof for targeted nucleic acid delivery and as a medicament.

The invention discloses a polypeptide targeting CD38, a ligand of the polypeptide, a coupling drug and application of the polypeptide, and the polypeptide targeting CD38 has an obvious binding signal with human CD38 protein, which shows that the polypeptide targeting CD38 has very high targeting property on CD38. A ligand or a coupling drug can be prepared from any sequence of the peptide targeting CD38, or a combination of a plurality of sequences, and an active drug is loaded or connected. The compound has a good killing result on cells such as MM.1 S, MOLP-8, HL-60, MV-4-11, Kasumi-1, K562 and KG-1, and has a relatively high growth inhibition rate on tumor cells such as a human multiple myeloma MOLP-8 cell strain and a human leukemia tumor cell HL-60 cell strain.

To provide a ligand binding to nectin-4 present on cancer cells, or a pharmaceutically acceptable salt thereof.SOLUTION: The present invention relates to heterotandem bicyclic peptide complexes comprising a first peptide ligand that binds to a component present on a cancer cell conjugated via a linker to a second peptide ligand that binds to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in the prevention, inhibition or treatment of cancer.SELECTED DRAWING: None

The invention discloses a proteolysis targeting chimera targeting a fibroblast growth factor receptor 1 as well as a preparation method and application of the proteolysis targeting chimera. According to the PROTAC degradation agent for targeted degradation of the FGFR1 protein developed on the basis of the FGFR protein small-molecule inhibitor, FGFR1 ligands and ligands of E3 ligase are coupled through different types of linkers with different chain lengths, and a series of PROTAC molecules targeted to the FGFR1 are successfully prepared. The proteolysis targeting chimera compound can effectively target FGFR1 protein and reduce the content of the FGFR1 protein, has good in-vivo activity, shows obvious anti-proliferation ability in human acute myeloid leukemia cells KG1a, can be used for preparing drugs for treating tumor diseases, and has good application prospects. The invention relates to a medicine, in particular to a medicine for treating breast cancer, non-small cell lung cancer, ovarian cancer, bladder cancer or head and neck squamous cell carcinoma.

The invention relates to a ligand drug conjugate with a free load recovery unit and an application of the ligand drug conjugate in prevention or treatment of diseases, the ligand drug conjugate can remove free loads through the connected recovery unit capable of being combined with the free loads, the medication safety is remarkably improved, and the application range of the ligand drug conjugate is widened. Meanwhile, the load carried by the ligand drug conjugate can be increased on the whole by recovering the free load, and the activity loss caused by load falling is made up. Therefore, by introducing the recovery unit, the recovery of the free load is realized, the safety and effectiveness of the ligand-coupled drug can be remarkably improved, and the therapeutic window is expanded.

According to the targeting ligand coupled drug compound and the preparation and application thereof, coupling of the targeting ligand and the drug is achieved through the annular nucleic acid, and the antibody drug conjugate with the high drug-antibody coupling ratio is smoothly prepared by means of the characteristics that the structure of the annular nucleic acid is stable, and the size and the number of coupling sites are adjustable; according to the present invention, the antibody drug conjugate has characteristics of closed structure, stable structure, programmable number and type of the coupled drugs, on-demand assembly, difficult degradation in the living body, smooth drug delivery to the tumor site, synergistic interaction, drug anti-tumor activity improving, and good anti-tumor effect, and can be used for the preparation of the anti-tumor drug conjugate, such that the anti-tumor drug conjugate has characteristics of good anti-tumor effect, good anti-tumor effect, and good anti-tumor effect. The development of antibody drug conjugates can be effectively promoted.

The present invention pertains to the technical field of medicine. Specifically disclosed are a dolastatin analogue, a ligand-drug conjugate thereof, a preparation method therefor, and use thereof. According to the present invention, a toxin, a linker, and a linker moiety are separately optimized, and the compound is prepared by means of organic synthesis. Also disclosed is use of the compound and the ligand-drug conjugate thereof in preparing a medicament for preventing and treating diseases, the diseases including but not limited to hyperproliferative diseases and angiogenic diseases, such as cancer, chronic metabolic diseases, and cardiovascular diseases. Further disclosed is a drug / pharmaceutical composition. The ligand-drug conjugate of the present invention offers the following effects: high stability, reduced off-target-induced toxicity, an expanded therapeutic window, a good tumor tissue-targeting property, and an excellent in vivo anti-tumor effect, achieving reduced toxicity and enhanced efficacy. The present invention provides a research foundation for preparing ligand-drug conjugates with high efficacy and low toxicity, having broad application prospects.

To provide methods for coupling a ligand to a composite material useful as a chromatographic separation medium.SOLUTION: Provided is a method for coupling a ligand to a functionalized composite material, comprising the steps of: a. providing a functionalized composite material, the functionalized composite material being arranged in a coplanar stack of coextensive sheets, a tubular configuration, or a spiral wound configuration, comprising: i. a support member comprising a plurality of pores extending through the support member; and ii. a macroporous cross-linked gel, the macroporous cross-linked gel comprising a polymer formed from a reaction of one or more polymerizable monomers with one or more cross-linkers, comprising pendant reactive functional groups, being located in the pores of the support member, and having macropores smaller than the pores of the support member; and b. flowing at a first flow rate a first solution substantially through or substantially across the functionalized composite material, the first solution comprising a plurality of first ligands, such that a plurality of covalent bonds forms between the reactive functional groups and the first ligands.SELECTED DRAWING: None

The invention belongs to the technical field of protein purification, and particularly relates to a chromatography medium, a preparation method of the chromatography medium and application of the chromatography medium in IgG extraction. The chromatography medium provided by the invention takes agarose as a matrix, and the surface of the agarose is activated by allyl glycidyl ether and modified by a ligand; wherein the ligand comprises purine of which the sixth position is substituted by amino or sulfydryl. The invention also provides a preparation method of the chromatography medium, which comprises the following steps: by taking agarose as a matrix, sequentially carrying out allyl glycidyl ether activation, bromo-alcoholization and ligand coupling on the agarose to obtain the chromatography medium. The chromatography medium provided by the invention has very high adsorption capacity and selectivity on dairy product IgG, and can be used for large-scale IgG preparation.

The invention belongs to the technical field of protein purification, and particularly relates to a chromatography medium, a preparation method of the chromatography medium and application of the chromatography medium to extraction of lactoferrin. The chromatography medium provided by the invention is prepared by taking agarose as a matrix, grafting a dextran extension chain on the surface in an activation manner and further coupling a ligand; wherein the molecular weight of the glucan ranges from 100 kDa to 500 kDa, the ligand comprises 2-mercaptobenzimidazole-5-sulfonic acid, and in the chromatography medium, the density of the ligand ranges from 200 [mu] mol / mL to 300 [mu] mol / mL. The invention also provides a preparation method, which comprises the following steps: sequentially carrying out epoxy activation, dextran modification, secondary activation and ligand coupling on the hydroxyl-containing matrix to obtain the hydroxyl-containing polymer. When being used for extracting lactoferrin from skimmed milk, the chromatography medium provided by the invention has the advantages of high loading capacity, high specific capturing capacity and high-efficiency regeneration, and realizes high-efficiency adsorption of lactoferrin and high-efficiency removal of impurities.

The invention relates to the technical field of biomedicine and targeted drug therapy, in particular to a USP7-targeted polypeptide and a polypeptide-proteolysis targeted chimera. The polypeptide targeting the USP7, provided by the invention, is a bioactive peptide obtained by adopting a phage display technology through multiple rounds of screening and high-throughput sequencing, and the polypeptide has relatively good cell membrane penetrability and can target the USP7. The polypeptide obtained through screening is used as a target protein ligand of the USP7, the USP7 target protein ligand is coupled with a specific E3 ligase ligand through a linker, and the polypeptide-proteolysis targeting chimera targeting the USP7 is constructed. The polypeptide-proteolysis targeting chimera not only can efficiently degrade USP7, but also can down-regulate PD-L1 on the surfaces of tumor cells, so that the tumor treatment effect is improved. Therefore, the invention can provide effective technical support for research and development of tumor targeted drugs and treatment of related cancers.

The invention relates to nucleic acid ligand conjugates and their use for delivery to cells. In particular, the present invention relates to a coupling product comprising a ligand linked to a nucleic acid. The invention also relates to methods of delivering nucleic acids to cells and treating diseases using the conjugate products. The invention also relates to a method of increasing uptake of a nucleic acid by a cell comprising coupling a nucleic acid with a ligand to form a coupling product of the invention.

Aspects of the present disclosure generally relate to an electrocatalyst. The electrocatalyst including a thio-modified carbon support. The thio-modified carbon support including a carbon support, the carbon support including a carbon black. A ligand is coupled to the carbon support. The ligand including a thiol group. The thio-modified carbon support including a metal catalyst coupled to the ligand.

A ligand-drug conjugate having a free payload recovery unit, and a use thereof in preventing or treating diseases. The ligand-drug conjugate can remove a free payload by means of a connected recovery unit capable of binding to the free payload, significantly improving the safety of medication. Moreover, by means of recovering the free payload, the payload carried by the ligand-drug conjugate as a whole can be increased, thereby compensating for activity loss caused by payload shedding. Therefore, by means of introducing the recovery unit, free payload is recovered, which can significantly increase the safety and effectiveness of the ligand-drug conjugate, and expand a treatment window.

The invention belongs to the technical field of medicines, and particularly discloses a dolastatin analogue and a ligand coupling medicine thereof as well as a preparation method and application of the dolastatin analogue and the ligand coupling medicine thereof. According to the invention, toxin, linker and linker parts are optimized respectively, and the compound is prepared through organic synthesis. The invention further discloses application of the compound and the ligand coupling medicine thereof in preparation of medicines for preventing and treating diseases, and the diseases include but not limited to hyperproliferative diseases and angiogenesis diseases, such as cancers, chronic metabolic diseases and cardiovascular diseases. The invention further discloses a medicine / medicine composition. The ligand coupling medicine has the following effects: the stability is high, and the toxicity caused by off-target is reduced; a higher therapeutic window; the tumor tissue targeting property is good; an excellent in-vivo anti-tumor effect is achieved, and the effects of reducing toxicity and improving efficiency are achieved. The invention provides a research basis for preparing a high-efficiency and low-toxicity ligand coupling medicine, and has a wide application prospect.

The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to EphA2, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.

The present invention relates to the technical field of recombinant protein and antibody purification, and in particular to a chromatography medium, a preparation method thereof, and an application thereof. The chromatography medium is formed by coupling a matrix and a ligand; the structural formula of the chromatography medium is shown in Formula I: wherein: Q is a matrix; L1 is a spacer arm; R1 is a methyl group or an ethyl group; R2 is an aromatic group; R3 is a linear alkyl group substituted with -OH, a substituted aromatic group, or a substituted cycloalkyl group; L2 is NH, O, S, or a covalent bond; and n=1 or 2. The chromatography medium of the present invention has a functional ligand with a specific structure and has a high adsorption capacity for proteins, so that the chromatography medium has an ionic and hydrophobic composite mode of action, which helps to improve separation efficiency, reduce purification process steps, reduce contaminant levels, and greatly reduce production costs. Furthermore, it is possible to obtain a product that meets quality standards with as few chromatography steps as possible.

The invention relates to a whole blood compatible matrix for coupling a ligand and use in extracorporeal blood treatment. The matrix comprises a solid substrate, said substrate comprising a first layer of polyethylene glycol (PEG) and at least a second layer of PEG, wherein said at least second layer is positioned outside the first layer and is bound to said first layer, and wherein the PEG of the at least second layer comprises a terminal functional group for coupling said ligand to said PEG. The invention further relates to a blood treatment device, comprising the matrix, wherein the matrix is whole blood compatible, and to the matrix comprising a ligand coupled thereto (apheresis matrix), and to a ligand coupled to the PEG of the apheresis matrix for use in the treatment of a medical condition by extracorporeal blood treatment.

The invention discloses a synthesis method of an iron-molybdenum coenzyme semi-topology structure simulation cluster. According to the invention, a ligand coupling bond breaking strategy is provided, precise ligand design is supplemented, the dissimilar metal cubic structure iron-sulfur cluster compound crystal is controllably prepared, and the dissimilar metal cubic structure iron-sulfur cluster compound crystal is high in stability in a nitrogen environment and not easy to decompose and lose efficacy; specifically, a new method can be provided for chemical synthesis of the iron-molybdenum coenzyme fine structure, a new reference is provided for chemical simulation of nitrogen fixation of the iron-molybdenum coenzyme fine structure, and a new direction is provided for exploration of a novel green efficient nitrogen activation catalyst.

Disclosed are methods for making targeting ligand-conjugated nucleotide phosphoramidites known as adem-A-GalNAc phosphoramidites, which can be used in the synthesis of oligonucleotides, such as therapeutic oligonucleotides.

This invention relates to the field of biology, and particularly to a ligand-coupled microsphere for measuring inverse-locking levels, its preparation method, and a method for measuring inverse-locking levels. The ligand-coupled microsphere comprises a ligand coupled with a first label, a DNA fragment, and a polystyrene microsphere. A second label is coupled to one end of the DNA fragment, and the second label specifically binds to the first label. Digoxigenin is coupled to the other end of the DNA fragment. An anti-digoxigenin antibody is coupled to the surface of the polystyrene microsphere, and the polystyrene microsphere is linked to the DNA fragment via the anti-digoxigenin antibody and digoxigenin. The measurement method of this invention can measure different receptor-ligand interactions and enables its application in commercial instruments, forming a more universal inverse-locking measurement method. This allows inverse-locking measurements to be applied in more situations, providing theoretical support for the engineering modification of various receptors such as TCR, and providing data support for clinical applications.

The invention provides a preparation method and application of an organoid induced exosome controlled release carrier. According to the method, specific therapeutic subtype exosomes are screened from disease model organs, and mild pre-activation treatment is combined, so that the immunoregulation and tissue repair functions of the exosomes are remarkably enhanced. The carrier is modified by double targeting ligands, a main ligand and an auxiliary ligand are coupled on the surface of the carrier through amido bonds, and focus cells and microenvironment cells are accurately targeted. A pH response-enzyme response dual triggering mechanism is adopted in the carrier design, fixed-point, fixed-time and quantitative release of the exosome is achieved, and the accuracy and durability of the treatment effect are ensured. The targeting property and the treatment efficiency are remarkably improved through a multi-synergistic mechanism, and the drug has a wide clinical application prospect, especially in the fields of tumor treatment and tissue repair.

The invention relates to the technical field of biology, in particular to a polypeptide skeleton chemical probe, a preparation method and application of the polypeptide skeleton chemical probe in receptor membrane protein identification. The polypeptide skeleton chemical probe comprises an enrichment module, a ligand coupling module, a polypeptide skeleton and a receptor crosslinking module. The polypeptide skeleton chemical probe is multifunctional, an enrichment module, a ligand coupling module and a receptor cross-linking module are connected to a polypeptide skeleton, and the enrichment module serves as a label and can be used for purification cross-linking of streptavidin beads and the like; the ligand coupling module can be used for carrying out chemical coupling with target secretory protein according to needs, the receptor crosslinking module enables the polypeptide skeleton chemical probe to be combined with a receptor and to be subjected to photo-crosslinking, enzymatic crosslinking and the like, and the polypeptide skeleton is a main skeleton and a connecting shaft of the whole probe and connects all functions together.